Visiopharm

We’re excited to present 6 posters at SITC this year! Will we see you there?   Each poster highlights unique aspects of our AI-driven workflows, from phenotyping to spatial metrics for immuno-oncology and beyond.   Meet our team and learn more about how we’re helping scientists push the boundaries of tissue analysis!   Check out our agenda at booth #716: https://lnkd.in/gwXuv-X7

Unsure how to take the first step over the edge into AI-supported biomarker assessments?   Visiopharm wants to help, and we are calling on pathology labs to apply for the opportunity to be selected as a Visiopharm Premier Partner! 📣   If you’re interested in using AI for biomarker assessment, this is your chance to be 1 of just 5 premier labs selected to access our new, fully automated HER2 or PD-L1 analysis solution — at no cost.   Selected Premier Partners will receive:   ✅ Exclusive access to our APP, platform, and AI experts at no cost for a dedicated study. ✅A valuable dataset, generated with our APP on your images, for publications, budgeting proposals, and showcasing innovation. ✅A bridge into AI, ensuring you to stay confident as you take the next step in your digital pathology journey.   Our AI experts, Jeni Caldara & Kirsten Anderson, will be at Pathology Visions (booth #400) and want to hear why your lab should be selected. Applicant meetings are limited, secure your space now: https://lnkd.in/dG-XEqzk #Stayconfident #VisiopharmPremierPartners #PathVisions

Counting down to #SITC2024 in Houston!   Join us at booth #716 during the annual meeting of the Society for Immunotherapy of Cancer (SITC) from November 6-10 to meet the Visiopharm team and explore our latest advancements in image analysis.   Here’s what you can expect:   🔍  We’ll be showcasing our Phenoplex™ software, featuring our advanced Spatial Neighborhood Analysis tools for understanding the tumor microenvironment and its impact on disease progression. 🔎  GeoMx DSP users can now harness Oncotopix® Discovery’s AI-driven capabilities to optimize tissue segmentation, accelerate ROI selection, and standardize results, enabling faster and more accurate data insights. 🔎  6 posters showcasing the power of AI-driven image analysis to unlock new insights in your research.   Have questions about spatial biology? Our experts, including Regan Baird, Amanda L., Daniel Winkowski, and James R. Mansfield, will be at the booth to chat and share insights.   Learn more: https://lnkd.in/gwXuv-X7 #SpatialBiology #Phenoplex #OncotopixDiscovery

We are on site in Dublin at the IHC User Group Meeting, hosted by the ACSLM and The IHC Network. Meet our Matthew Burke PhD and get a demo of Qualitopix to learn, how you can monitor and document your IHC staining consistency. This is increasingly important with predictive cutoffs in the lower expression ranges, like for HER2-low. If you are not in Dublin today, check out more details here: https://lnkd.in/dEqQp6wC #qualitopix #Her2low #ihcstaining

Multiplex users: are you confident in your results?   When it comes to multiplex image analysis, quality control (QC) to ensure accurate phenotyping  can be a challenge. Most researchers have limited options for identifying QC issues during the process — leading to uncertainty about the reliability of their data.   In our latest whitepaper, we demonstrated how the Phenoplex Guided Workflow sets new standards by allowing researchers to define positivity conditions for each biomarker based on intensity and cellular distribution.   In the case study, we wanted to understand the spatial distribution of cytotoxic T cells and NK cells relative to each other and within the various microdomains of the tissue map we had generated. The interactive Co-Occurrence Matrix in Phenoplex allowed us to quickly see the number of co-expressing cells for each biomarker pair to quickly QC settings and adjust positivity gates as needed.   Want to see how this can enhance your research? 👉 Explore the full whitepaper here: https://lnkd.in/ekStF9Ac

Webinar Tomorrow 📣 Join us as Florence A., Histology Project Manager at Novalix, presents a compelling case study on how advanced image analysis is enhancing our understanding of Autosomal Dominant Polycystic Kidney Disease (ADPKD). She’ll showcase how the PCKD mouse model is being used to mimic human PKD1 mutations and uncover new insights into ADPKD. 🗓️ Date: October 10 🕓 Time: 4 PM CEST Why Attend? Gain insights into innovative imaging techniques and their impact on unravelling ADPKD pathology. Plus, ask your questions during our live Q&A! 👉 Register now: https://lnkd.in/dpvbq38p #ADPKD #KidneyResearch #ImageAnalysis

New Research alert 💡 A study led by Maaike-Anna Hempenius et al. evaluates the consistency of HER2-low detection in breast cancer across 35 Dutch labs.     Using standardized cell lines covering the dynamic range of HER2 expression and a calibrator with Visiopharm's Qualitopix™ software to quantify the respective staining intensities, the team analyzed the HER2 staining variability, revealing a pressing need for assay standardization.    Accurate detection of HER2-low levels is vital for identifying patients eligible for trastuzumab-deruxtecan treatment.    Read the article and discover how Qualitopix can enhance HER2 staining consistency: https://lnkd.in/d7z7KKh5 Shout out to all the authors: Maaike-Anna Hempenius, Maran Eenkhoorn, Henrik Høeg, David J Dabbs, Bert van der Vegt,  Seshi R Sompuram, Nils 't Hart And our partners: HistoCyte Laboratories Ltd (HER2-specific dynamic range cell lines) Boston Cell Standards (IHC calibrators). #StayConsistent #BreastCancerAwarenessMonth #Qualitopix

Heading to Pathology Visions in Orlando? We are ☀️ Here’s a preview of what we’re showcasing: 1) New HER2 algorithm: a fully automated single-cell approach for whole slide HER2 IHC quantification aligned with ASCO/CAP guidelines. Keep an eye out for more details coming soon! Learn more here: https://lnkd.in/dftEAwWc 2) Seamless Integration: Learn how Visiopharm fits effortlessly into your PACS/IMS for a truly automated workflow—from scanning to reviewing. 3) Qualitopix: a complete workflow for staining consistency. 4) Visiopharm Partner Showdown: Exciting news coming your way! Stay tuned. Come by booth #400 and meet Jeni Caldara, Kirsten Anderson & Kyle R. Kisiel. #PathVisions2024 #Stayconfident

Packed house for David Mason's presentation at the 3rd North West Melanoma Meeting at the University of Liverpool! Today, he’s showcasing Visiopharm’s Deep Learning tools alongside our new data exploration features for multiplex image analysis. A big thank you to the organizers for hosting us—it’s always a pleasure connecting with the research community! 

In today’s #VisiopharmAPP chapter, we’re highlighting our IVDR-cleared APP for detecting and scoring Ki-67 in breast cancer.   💡 Why is this APP important? Manual detection and scoring of Ki67 are difficult and prone to variability, limiting its clinical utility. Automated scoring through digital image analysis (DIA) offers a more reliable assessment.   Our Ki-67 APP is fully automated and does not require manual input during analysis. It consists of four analysis steps that automatically separate sample tissue from control tissues, identify invasive cancer areas, count tumor nuclei based on Ki-67 expression, and calculate the proliferation index for the entire tumor area. Optionally, visualization of the proliferation distribution can be added as a heatmap, and identification of a customizable hot spot can be added, with an export of the respective proliferation index for the hotspot.   Pathology experts at the University Medical Center Groningen recently published a paper demonstrating the outstanding performance of Visiopharm’s Ki-67 algorithm: https://lnkd.in/dPAr9WES   👉 Learn more about our Ki-67 APP: https://lnkd.in/diRzC5Nj #BreastCancerAwarenessMonth